Development of canadian recommendations for the management of anca-associated vasculitides: Results of the national needs assessment questionnaire

Open Rheumatology Journal

Volumn 9, Issue , 2015, Pages 16-20

  Famorca, Leilani ^a   Twilt, Marinka ^b   Barra, Lillian ^c   Bakowsky, Volodko ^d   Benseler, Susanne ^e   Cabral, David ^f   Carette, Simon ^g   Dhindsa, Navjot ^h   Fifi Mah, Aurore ⁱ   Goulet, Michelle ^j   Khalidi, Nader ^k   Khraishi, Majed ^l   Mc geoch, Lucy ^g   Milman, Nataliya ^m   Pineau, Christian ⁿ   Shojania, Kam ^o   Taylor Gjevre, Regina ^p   Towheed, Tanveer ^q   Trudeau, Judith ^r   Yacyshyn, Elaine ^s   Liang, Patrick ^t   Pagnoux, Christian ^g   more..

^a Langs Community Centre   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c ST JOSEPH S HEALTH CENTRE   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e ALBERTA CHILDREN'S HOSPITAL   (Canada)

^f BC CHILDREN S HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^k MCMASTER UNIVERSITY   (Canada)

^l MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^m Ottawa Hospital   (Canada)

ⁿ MCGILL UNIVERSITY   (Canada)

^o VANCOUVER GENERAL HOSPITAL   (Canada)

^p ROYAL UNIVERSITY HOSPITAL   (Canada)

^q QUEEN S UNIVERSITY   (Canada)

^r Division of Rheumatology   (Canada)

^s UNIVERSITY OF ALBERTA   (Canada)

^t CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

more..

Author keywords

ANCA associated vasculitis; Can Vasc; Physician practice patterns

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; CANADIAN; CANADIAN NEPHROLOGY SOCIETY; CANADIAN THORACIC SOCIETY; CLINICAL PRACTICE; DEMOGRAPHY; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH SURVEY; HUMAN; MALE; PRIORITY JOURNAL; REMISSION; RHEUMATOLOGY;

EID: 84930195451     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/18743129014090100016     Document Type: Article

References (12)

1. [1] Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11.
2. [2] Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 2009; 48: 1560-5.
3. [3] Gibelin A, Maldini C, Mahr A. Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement. Semin Respir Crit Care Med 2011; 32: 264-73.
4. [4] Anderson K, Klassen J, Stewart SA, Taylor-Gjevre RM. Does geographic location affect incidence of ANCA-associated renal vasculitis in northern Saskatchewan, Canada? Rheumatology (Oxford) 2013; 52: 1840-4.
5. [5] Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
6. [6] Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-20.
7. [7] Bykerk VP, Schieir O, Akhavan P, Hazlewood GS, Cheng CK, Bombardier C. Emerging issues in pharmacological management of rheumatoid arthritis: results of a national needs assessment survey identifying practice variations for the development of Canadian Rheumatology Association clinical practice recommendations. J Rheumatol 2012; 39: 1555-8.
8. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 139-274.
9. [9] Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012; 39: 125-30.
10. [10] Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012; 64: 3770-8.
11. [11] Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2012; 64: 3760-9.
12. [12] Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. N Engl J Med 2014; 371: 1771-80.